Recommended Alerts

Sign Up For Alerts

China’s NMPA Proposes Implementing Regulations for the Drug Administration Law

China’s National Medical Products Administration (“NMPA”) recently announced a comprehensive draft amendment (“Draft Amendment”) to the Implementation Regulation of the PRC Drug Administration Law (“DAL Implementing Regulations”). The NMPA is soliciting public comments on the Draft Amendment through June 9, 2022.

Read More

China FDA Publishes Draft Measures to Accelerate Medical Device Approvals

Practices: China Life Sciences

Printer-Friendly Version

Cookie Settings